Evidence map›Paper›PMID 42830389›Full record

ArticleImmunologic research2026

Augmenting antitumor immunity in colon cancer via GSDMD-mediated pyroptosis induced by an attenuated Salmonella delivery system.

Bingran Han, Xu Si, Chuanjie Liu, Ziwei Ai, Jingyuan Zhu, Xurui Chai, Pengkun Wei, Zhiang Liu, Xiaolong Jia, Sheng Guo and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Immunologic research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Bingran Han *Xinxiang Engineering Technology Research Center of immune checkpoint drug for Liver- Intestinal Tumors, School of Basic Medical Sciences, Henan Medical University, Xinxiang, Henan, 453000, PR China.
Xu Si *Junji College Of Henan Medical University, Xinxiang, Henan, 453000, PR China.
Chuanjie LiuXinxiang Engineering Technology Research Center of immune checkpoint drug for Liver- Intestinal Tumors, School of Basic Medical Sciences, Henan Medical University, Xinxiang, Henan, 453000, PR China.
Ziwei AiXinxiang Engineering Technology Research Center of immune checkpoint drug for Liver- Intestinal Tumors, School of Basic Medical Sciences, Henan Medical University, Xinxiang, Henan, 453000, PR China.
Jingyuan ZhuXinxiang Engineering Technology Research Center of immune checkpoint drug for Liver- Intestinal Tumors, School of Basic Medical Sciences, Henan Medical University, Xinxiang, Henan, 453000, PR China.
Xurui ChaiXinxiang Engineering Technology Research Center of immune checkpoint drug for Liver- Intestinal Tumors, School of Basic Medical Sciences, Henan Medical University, Xinxiang, Henan, 453000, PR China.
Pengkun WeiXinxiang Engineering Technology Research Center of immune checkpoint drug for Liver- Intestinal Tumors, School of Basic Medical Sciences, Henan Medical University, Xinxiang, Henan, 453000, PR China.
Zhiang LiuXinxiang Engineering Technology Research Center of immune checkpoint drug for Liver- Intestinal Tumors, School of Basic Medical Sciences, Henan Medical University, Xinxiang, Henan, 453000, PR China.
Xiaolong JiaMedical College, Xinxiang University, Xinxiang, Henan, 453000, PR China.
Sheng GuoXinxiang Engineering Technology Research Center of immune checkpoint drug for Liver- Intestinal Tumors, School of Basic Medical Sciences, Henan Medical University, Xinxiang, Henan, 453000, PR China.
Tiesuo ZhaoXinxiang Engineering Technology Research Center of immune checkpoint drug for Liver- Intestinal Tumors, School of Basic Medical Sciences, Henan Medical University, Xinxiang, Henan, 453000, PR China. zhaotiesuo1106@163.com.
Huijie JiaXinxiang Engineering Technology Research Center of immune checkpoint drug for Liver- Intestinal Tumors, School of Basic Medical Sciences, Henan Medical University, Xinxiang, Henan, 453000, PR China. zhongziqi1115@163.com.

Funding

Innovation and Entrepreneurship Training Programmed for college student 202510472016Innovation and Entrepreneurship Training Programmed for college student 202510472056Key Projects of Scientific Research for Higher Education of Henan Province 25A310005Key Projects of Scientific Research for Higher Education of Henan Province 26A310003Natural Science Foundation of Henan Province 252300423184Xinxiang University Doctoral Start-up Grant 1366020279
6 · The paper itself

Abstract

As a major gastrointestinal malignancy, colon cancer (CC) demands more effective therapies. Gene therapy is an emerging promising strategy, and pyroptosis, a novel lytic cell death form, serves as a vital antitumor target, with Gasdermin D (GSDMD)-a key pore-forming protein in pyroptosis-showing anti-CC potential. We constructed an engineered attenuated Salmonella strain to deliver a GSDMD-expressing plasmid, and verified its therapeutic efficacy via in vitro and in vivo studies. In CC cell lines, the Salmonella vector upregulated GSDMD and cleaved caspase-1 (its upstream activator), inhibiting cell proliferation and inducing pyroptosis. In CC-bearing mice, the strain significantly suppressed tumor progression, reduced Ki67 expression, elevated intratumoral GSDMD and cleaved caspase-1 levels, and enhanced CD4

Indexed as

Colonic NeoplasmsGenetic TherapyIntracellular Signaling Peptides and ProteinsPhosphate-Binding ProteinsPyroptosisSalmonellaAnimalsCaspase 1CD8-Positive T-LymphocytesCell Line, TumorFemaleGasderminsGenetic VectorsHumansMiceCaspase 1GasderminsGSDMD protein, humanGsdmd protein, mouseIntracellular Signaling Peptides and ProteinsPhosphate-Binding ProteinsAntitumor immunityColorectal cancerGSDMD

Identifiers

PMID42830389

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.